What Is Ipamorelin and How Does It Work
Ipamorelin is a pentapeptide classified as a selective growth hormone secretagogue - it mimics ghrelin at the pituitary gland's ghrelin receptor (GHS-R1a), triggering a clean, pulsatile release of growth hormone. What distinguishes it from older-generation secretagogues in the same class (GHRP-2, GHRP-6, hexarelin) is receptor selectivity: those earlier compounds also stimulate cortisol and prolactin release as a side effect of their broader receptor activity, while Ipamorelin's more selective binding profile largely avoids that spillover in research models.
Because it works through a different receptor pathway than GHRH analogs like CJC-1295 or Sermorelin, Ipamorelin is frequently studied in combination with them rather than alone - the two mechanisms are additive, producing a larger GH pulse than either compound triggers independently.
Research Dosing
Dosing below reflects ranges reported in published research and common research-protocol conventions, not personal medical guidance.
| Dose | Frequency | Timing | Route |
|---|---|---|---|
| 200–300mcg | 1–3× daily | Fasted - pre-sleep, pre-training, or on waking | SubQ injection |
Context: The fasted-state requirement is not optional in the research protocols this dosing is drawn from - insulin elevation after eating blunts the GH pulse these compounds are designed to trigger. Pre-sleep dosing is considered the most important single injection, aligning with the dominant natural GH pulse during slow-wave sleep.
Regulatory Status
Ipamorelin is not an FDA-approved drug and is not currently listed on the FDA's 503A or 503B bulk drug substance lists for compounding pharmacies. Products sold as "Ipamorelin" - including the one carried in the BioStackIQ shop - are marketed and sold as research chemicals for laboratory and research use only, not for human consumption. Consult a qualified healthcare provider before considering any peptide protocol.
What Research Shows
The foundational human research on Ipamorelin's receptor selectivity dates to the late 1990s, when it was first characterized as a selective GH secretagogue distinct from earlier GHRP compounds - specifically for its reduced effect on cortisol and prolactin at doses that still produced robust GH release.
For the combined CJC-1295 + Ipamorelin stacking protocol - dosing schedule, timing around sleep and training, and cycle structure - see the peptide stacks for muscle growth guide.